Sham Mailankody

Hematology | Oncology
530 E 74th St
New York, NY 10021

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 186 publications

Bispecific CAR T for extramedullary myeloma: a minute waltz.

Bispecific CAR T for extramedullary myeloma: a minute waltz.

Journal: Blood
Published: August 13, 2026

More options, more questions in the management of early relapsed and/or refractory multiple myeloma.

More options, more questions in the management of early relapsed and/or refractory multiple myeloma.

Journal: Nature reviews. Clinical oncology
Published: July 31, 2026

Robust CD4+ CAR T cell expansion is associated with non-ICANS neurotoxicities after ciltacabtagene autoleucel in patients with multiple myeloma.

Robust CD4+ CAR T cell expansion is associated with non-ICANS neurotoxicities after ciltacabtagene autoleucel in patients with multiple myeloma.

Journal: Science translational medicine
Published: July 29, 2026

Lesion-level PET/CT analysis to identify predictors of progression after BCMA CAR T-cell therapy in multiple myeloma.

Lesion-level PET/CT analysis to identify predictors of progression after BCMA CAR T-cell therapy in multiple myeloma.

Journal: Blood cancer journal
Published: June 18, 2026

CAR T cells take on precancers.

CAR T cells take on precancers.

Journal: Nature medicine
Published: June 17, 2026

Patient-Specific Determinants of Response to BCMA- and GPRC5D-Targeted CAR T-Cell Therapy in Multiple Myeloma: A QSP Analysis of Clinical Trial and Real-World Data.

Patient-Specific Determinants of Response to BCMA- and GPRC5D-Targeted CAR T-Cell Therapy in Multiple Myeloma: A QSP Analysis of Clinical Trial and Real-World Data.

Journal: Clinical pharmacology and therapeutics
Published: February 26, 2026

Lenalidomide-Related Diarrhea in Patients with Multiple Myeloma is Associated with Gut Microbiota Dysbiosis and Disruption of the Bile Acid Pool.

Lenalidomide-Related Diarrhea in Patients with Multiple Myeloma is Associated with Gut Microbiota Dysbiosis and Disruption of the Bile Acid Pool.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 23, 2026

A pilot trial evaluating lenalidomide and oral azacitidine with radiotherapy for patients with newly diagnosed and relapsed plasmacytoma.

A pilot trial evaluating lenalidomide and oral azacitidine with radiotherapy for patients with newly diagnosed and relapsed plasmacytoma.

Journal: Haematologica
Published: February 05, 2026

Low Dose Tocilizumab for Mitigation of Cytokine Release Syndrome With T-Cell Engaging Bispecific Antibodies.

Low Dose Tocilizumab for Mitigation of Cytokine Release Syndrome With T-Cell Engaging Bispecific Antibodies.

Journal: Clinical lymphoma, myeloma & leukemia
Published: January 30, 2026

Pharmacokinetics of CAR T cells in multiple myeloma - the good, the bad, and the ugly.

Pharmacokinetics of CAR T cells in multiple myeloma - the good, the bad, and the ugly.

Journal: Leukemia
Published: January 08, 2026

Plasma cell identity escape drives resistance to anti-BCMA T-cell-redirecting therapy in multiple myeloma.

Plasma cell identity escape drives resistance to anti-BCMA T-cell-redirecting therapy in multiple myeloma.

Journal: bioRxiv : the preprint server for biology
Published: December 19, 2025

Robust CD4+ CAR T cell Expansion Is Associated with Non-ICANS Neurotoxicities Following Ciltacabtagene Autoleucel.

Robust CD4+ CAR T cell Expansion Is Associated with Non-ICANS Neurotoxicities Following Ciltacabtagene Autoleucel.

Journal: medRxiv : the preprint server for health sciences
Published: November 24, 2025
Showing 1-12 of 186

Last Updated: 09/26/2026